Di FDA don align on key elements of one Phase 3 study for Zervimesine, one drug wey dem dey develop to treat dementia with Lewy bodies. Psychiatric Times report say the agreement on the trial plan na one important stage for the drug.
Di news come one day after Longevity.Technology report say the Lewy body drug candidate get patent cover wey go run reach 2045.
Di mata don dey pull attention for posts on X, as the condition and the drug development dey generate conversation.
Dementia with Lewy bodies no be small condition. News Medical explain say na the second most common type of degenerative dementia after Alzheimer’s disease, and dem dey diagnose am when person show the characteristic symptoms.
Lewy body disease, the general name wey cover Parkinson’s disease and Lewy body dementia, dey start when alpha-synuclein protein misfold for brain. Oskar Hansson, Professor of Neurology for Lund University and senior consultant for Skåne University Hospital, explain say the protein dey clump together and form Lewy bodies wey damage nerve cells.
Which name dem go use depend on the symptom wey dey dominate. Science Daily explain say when movement difficulties dey more, dem dey call am Parkinson’s disease, but when cognitive impairments dey dominant, dem dey use the term Lewy body dementia.
Until recently, doctors no fit tok with certainty whether person wey get movement difficulties or cognitive problems carry Lewy bodies for brain until after the person die. But research from Lund University show say spinal fluid test now fit detect the misfolded protein.
Dem publish the work for Nature Medicine, and dem also report am for the Alzheimer’s Association International Conference. Di study carry over 1,100 individuals, and none of them bin show any cognitive impairment or motor difficulty at the beginning.
Di researchers also find say reduced sense of smell dey strongly linked to Lewy body disease, even before other clear symptoms show.
